NFKB1 and B-cell chronic lymphocytic leukemia: MEC-1 cells were treated for 24 hours with either IT-901, a NF-κB inhibitor that has been proven efficient in inhibiting NF-κB in CLL cells (24), or LPS, a known activator of the NF-κB pathway (39), or a combination of both.